Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
Identifieur interne : 001448 ( Main/Exploration ); précédent : 001447; suivant : 001449Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
Auteurs : Zai-Li Zhang [République populaire de Chine] ; Han Zhong [République populaire de Chine] ; Yang-Xi Liu [République populaire de Chine] ; Ke-Jia Le [République populaire de Chine] ; Min Cui [République populaire de Chine] ; Yue-Tian Yu [République populaire de Chine] ; Zhi-Chun Gu [République populaire de Chine] ; Yuan Gao [République populaire de Chine] ; Hou-Wen Lin [République populaire de Chine]Source :
- Annals of translational medicine [ 2305-5839 ] ; 2020.
Abstract
Background
Coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, first manifested in December 2019, and spread rapidly worldwide. Facing this lethal disease, there is an urgent need to develop potent therapies against SARS-CoV-2 infection. SARS-CoV-2 phylogenetically and symptomatically resembles SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Numerous agents have been utilised during the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) epidemics, which may show some benefit against SARS-CoV-2.
Methods
MEDLINE, EMBASE, Cochrane Library, CBM Disc, China National Knowledge Infrastructure, Wanfang Data, and the China Science and Technology Journal Database will be searched. Manual searches will be conducted by searching pre-printing websites, clinical trial registers, and screening the reference lists of inclusive studies. The screening of all citations and the selection of inclusive articles will be conducted by two reviewers. Randomised controlled trials (RCTs) and controlled cohort studies reporting antiviral therapies, including ribavirin, remdesivir, lopinavir/ritonavir, arbidol, chloroquine, hydroxychloroquine, and interferon, for SARS, MERS, and COVID-19 will be included. The primary outcomes will be mortality, incidence of acute respiratory distress syndrome, and utilisation of mechanical ventilation and intensive care unit admission. The secondary outcomes will be improvement in symptoms and chest radiography results, virus clearance, changes in blood test results, and serum tests. The quality of the retrieved RCTs and observational studies will be appraised according to the Cochrane risk of bias tool and the Newcastle-Ottawa Scale, respectively. If feasible, we will perform a fixed- or random-effects meta-analysis.
Discussion
This systematic review and meta-analysis will summarise all the available evidence for the efficacy and safety of current therapeutic options in SARS-CoV, MERS-CoV, or SARS-CoV-2-infected patients. The findings of this study may inform subsequent antiviral interventions for patients with COVID-19.
Study registration
The protocol of this study has been submitted to the PROSPERO platform (https://www.crd.york.ac.uk/PROSPERO/), and the registration number is CRD42020168639.
DOI: 10.21037/atm-20-2340
PubMed: 33313272
PubMed Central: PMC7729372
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.</title><author><name sortKey="Zhang, Zai Li" sort="Zhang, Zai Li" uniqKey="Zhang Z" first="Zai-Li" last="Zhang">Zai-Li Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhong, Han" sort="Zhong, Han" uniqKey="Zhong H" first="Han" last="Zhong">Han Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Yang Xi" sort="Liu, Yang Xi" uniqKey="Liu Y" first="Yang-Xi" last="Liu">Yang-Xi Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Le, Ke Jia" sort="Le, Ke Jia" uniqKey="Le K" first="Ke-Jia" last="Le">Ke-Jia Le</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Cui, Min" sort="Cui, Min" uniqKey="Cui M" first="Min" last="Cui">Min Cui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Yue Tian" sort="Yu, Yue Tian" uniqKey="Yu Y" first="Yue-Tian" last="Yu">Yue-Tian Yu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Gu, Zhi Chun" sort="Gu, Zhi Chun" uniqKey="Gu Z" first="Zhi-Chun" last="Gu">Zhi-Chun Gu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Gao, Yuan" sort="Gao, Yuan" uniqKey="Gao Y" first="Yuan" last="Gao">Yuan Gao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Lin, Hou Wen" sort="Lin, Hou Wen" uniqKey="Lin H" first="Hou-Wen" last="Lin">Hou-Wen Lin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33313272</idno><idno type="pmid">33313272</idno><idno type="doi">10.21037/atm-20-2340</idno><idno type="pmc">PMC7729372</idno><idno type="wicri:Area/Main/Corpus">000674</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000674</idno><idno type="wicri:Area/Main/Curation">000674</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000674</idno><idno type="wicri:Area/Main/Exploration">000674</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.</title><author><name sortKey="Zhang, Zai Li" sort="Zhang, Zai Li" uniqKey="Zhang Z" first="Zai-Li" last="Zhang">Zai-Li Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhong, Han" sort="Zhong, Han" uniqKey="Zhong H" first="Han" last="Zhong">Han Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Yang Xi" sort="Liu, Yang Xi" uniqKey="Liu Y" first="Yang-Xi" last="Liu">Yang-Xi Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Le, Ke Jia" sort="Le, Ke Jia" uniqKey="Le K" first="Ke-Jia" last="Le">Ke-Jia Le</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Cui, Min" sort="Cui, Min" uniqKey="Cui M" first="Min" last="Cui">Min Cui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Yu, Yue Tian" sort="Yu, Yue Tian" uniqKey="Yu Y" first="Yue-Tian" last="Yu">Yue-Tian Yu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Gu, Zhi Chun" sort="Gu, Zhi Chun" uniqKey="Gu Z" first="Zhi-Chun" last="Gu">Zhi-Chun Gu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Gao, Yuan" sort="Gao, Yuan" uniqKey="Gao Y" first="Yuan" last="Gao">Yuan Gao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Lin, Hou Wen" sort="Lin, Hou Wen" uniqKey="Lin H" first="Hou-Wen" last="Lin">Hou-Wen Lin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of translational medicine</title><idno type="ISSN">2305-5839</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>Background</b></p><p>Coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, first manifested in December 2019, and spread rapidly worldwide. Facing this lethal disease, there is an urgent need to develop potent therapies against SARS-CoV-2 infection. SARS-CoV-2 phylogenetically and symptomatically resembles SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Numerous agents have been utilised during the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) epidemics, which may show some benefit against SARS-CoV-2.</p></div><div type="abstract" xml:lang="en"><p><b>Methods</b></p><p>MEDLINE, EMBASE, Cochrane Library, CBM Disc, China National Knowledge Infrastructure, Wanfang Data, and the China Science and Technology Journal Database will be searched. Manual searches will be conducted by searching pre-printing websites, clinical trial registers, and screening the reference lists of inclusive studies. The screening of all citations and the selection of inclusive articles will be conducted by two reviewers. Randomised controlled trials (RCTs) and controlled cohort studies reporting antiviral therapies, including ribavirin, remdesivir, lopinavir/ritonavir, arbidol, chloroquine, hydroxychloroquine, and interferon, for SARS, MERS, and COVID-19 will be included. The primary outcomes will be mortality, incidence of acute respiratory distress syndrome, and utilisation of mechanical ventilation and intensive care unit admission. The secondary outcomes will be improvement in symptoms and chest radiography results, virus clearance, changes in blood test results, and serum tests. The quality of the retrieved RCTs and observational studies will be appraised according to the Cochrane risk of bias tool and the Newcastle-Ottawa Scale, respectively. If feasible, we will perform a fixed- or random-effects meta-analysis.</p></div><div type="abstract" xml:lang="en"><p><b>Discussion</b></p><p>This systematic review and meta-analysis will summarise all the available evidence for the efficacy and safety of current therapeutic options in SARS-CoV, MERS-CoV, or SARS-CoV-2-infected patients. The findings of this study may inform subsequent antiviral interventions for patients with COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>Study registration</b></p><p>The protocol of this study has been submitted to the PROSPERO platform (https://www.crd.york.ac.uk/PROSPERO/), and the registration number is CRD42020168639.</p></div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33313272</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2305-5839</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>22</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Annals of translational medicine</Title><ISOAbbreviation>Ann Transl Med</ISOAbbreviation></Journal><ArticleTitle>Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.</ArticleTitle><Pagination><MedlinePgn>1527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/atm-20-2340</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, first manifested in December 2019, and spread rapidly worldwide. Facing this lethal disease, there is an urgent need to develop potent therapies against SARS-CoV-2 infection. SARS-CoV-2 phylogenetically and symptomatically resembles SARS-CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Numerous agents have been utilised during the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) epidemics, which may show some benefit against SARS-CoV-2.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">MEDLINE, EMBASE, Cochrane Library, CBM Disc, China National Knowledge Infrastructure, Wanfang Data, and the China Science and Technology Journal Database will be searched. Manual searches will be conducted by searching pre-printing websites, clinical trial registers, and screening the reference lists of inclusive studies. The screening of all citations and the selection of inclusive articles will be conducted by two reviewers. Randomised controlled trials (RCTs) and controlled cohort studies reporting antiviral therapies, including ribavirin, remdesivir, lopinavir/ritonavir, arbidol, chloroquine, hydroxychloroquine, and interferon, for SARS, MERS, and COVID-19 will be included. The primary outcomes will be mortality, incidence of acute respiratory distress syndrome, and utilisation of mechanical ventilation and intensive care unit admission. The secondary outcomes will be improvement in symptoms and chest radiography results, virus clearance, changes in blood test results, and serum tests. The quality of the retrieved RCTs and observational studies will be appraised according to the Cochrane risk of bias tool and the Newcastle-Ottawa Scale, respectively. If feasible, we will perform a fixed- or random-effects meta-analysis.</AbstractText><AbstractText Label="Discussion" NlmCategory="UNASSIGNED">This systematic review and meta-analysis will summarise all the available evidence for the efficacy and safety of current therapeutic options in SARS-CoV, MERS-CoV, or SARS-CoV-2-infected patients. The findings of this study may inform subsequent antiviral interventions for patients with COVID-19.</AbstractText><AbstractText Label="Study registration" NlmCategory="UNASSIGNED">The protocol of this study has been submitted to the PROSPERO platform (https://www.crd.york.ac.uk/PROSPERO/), and the registration number is CRD42020168639.</AbstractText><CopyrightInformation>2020 Annals of Translational Medicine. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zai-Li</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang-Xi</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Ke-Jia</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yue-Tian</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zhi-Chun</ForeName><Initials>ZC</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hou-Wen</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Transl Med</MedlineTA><NlmUniqueID>101617978</NlmUniqueID><ISSNLinking>2305-5839</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus (MERS)</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome (SARS)</Keyword><Keyword MajorTopicYN="N">therapeutic options</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-2340). ZCG and YTY serve as unpaid section editors of Annals of Translational Medicine from Oct 2019 to Sep 2020. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33313272</ArticleId><ArticleId IdType="doi">10.21037/atm-20-2340</ArticleId><ArticleId IdType="pii">atm-08-22-1527</ArticleId><ArticleId IdType="pmc">PMC7729372</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Feb 18;368:m641</Citation><ArticleIdList><ArticleId IdType="pubmed">32071063</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 15;70(9):1837-1844</Citation><ArticleIdList><ArticleId IdType="pubmed">31925415</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Oct 18;343:d5928</Citation><ArticleIdList><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Vopr Virusol. 2008 Jul-Aug;53(4):9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18756809</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation><ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):211-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16261199</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation><ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):221-236</Citation><ArticleIdList><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 May 19;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32838353</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Trop Med Int Health. 2004 Aug;9(8):923-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15303999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pharm. 2014 Dec;36(6):1230-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25330865</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):69-71</Citation><ArticleIdList><ArticleId IdType="pubmed">31996494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Chem. 2020 Sep 1;201:112527</Citation><ArticleIdList><ArticleId IdType="pubmed">32563812</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1827-1837</Citation><ArticleIdList><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2018 Oct;52(4):443-450</Citation><ArticleIdList><ArticleId IdType="pubmed">30012440</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2009 Oct;62(10):e1-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation><ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Apr;92(4):418-423</Citation><ArticleIdList><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2018 May;28(3):e1977</Citation><ArticleIdList><ArticleId IdType="pubmed">29664167</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 May;92(5):479-490</Citation><ArticleIdList><ArticleId IdType="pubmed">32052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2019 Jul - Aug;30:9-18</Citation><ArticleIdList><ArticleId IdType="pubmed">31252170</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhang, Zai Li" sort="Zhang, Zai Li" uniqKey="Zhang Z" first="Zai-Li" last="Zhang">Zai-Li Zhang</name></noRegion><name sortKey="Cui, Min" sort="Cui, Min" uniqKey="Cui M" first="Min" last="Cui">Min Cui</name><name sortKey="Gao, Yuan" sort="Gao, Yuan" uniqKey="Gao Y" first="Yuan" last="Gao">Yuan Gao</name><name sortKey="Gu, Zhi Chun" sort="Gu, Zhi Chun" uniqKey="Gu Z" first="Zhi-Chun" last="Gu">Zhi-Chun Gu</name><name sortKey="Le, Ke Jia" sort="Le, Ke Jia" uniqKey="Le K" first="Ke-Jia" last="Le">Ke-Jia Le</name><name sortKey="Lin, Hou Wen" sort="Lin, Hou Wen" uniqKey="Lin H" first="Hou-Wen" last="Lin">Hou-Wen Lin</name><name sortKey="Liu, Yang Xi" sort="Liu, Yang Xi" uniqKey="Liu Y" first="Yang-Xi" last="Liu">Yang-Xi Liu</name><name sortKey="Yu, Yue Tian" sort="Yu, Yue Tian" uniqKey="Yu Y" first="Yue-Tian" last="Yu">Yue-Tian Yu</name><name sortKey="Zhong, Han" sort="Zhong, Han" uniqKey="Zhong H" first="Han" last="Zhong">Han Zhong</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001448 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001448 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33313272
|texte= Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33313272" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |